Regeneron Pharmaceuticals Inc.

530.48+2.99+0.57%Vol 535.63K1Y Perf -10.40%
Jun 16th, 2021 13:23 DELAYED
BID530.22 ASK530.58
Open531.17 Previous Close527.49
Pre-Market529.85 After-Market-
 2.36 0.45%  - -
Target Price
622.21 
Analyst Rating
Moderate Buy 1.95
Potential %
17.13 
Finscreener Ranking
★★★★+     58.53
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     59.55
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     77.19
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap56.52B 
Earnings Rating
Neutral
Price Range Ratio 52W %
40.01 
Earnings Date
4th Aug 2021

Today's Price Range

529.61542.42

52W Range

441.00664.64

5 Year PE Ratio Range

12.7099.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
1.08%
1 Month
2.10%
3 Months
9.40%
6 Months
8.41%
1 Year
-10.40%
3 Years
67.30%
5 Years
43.92%
10 Years
829.99%

TickerPriceChg.Chg.%
REGN530.482.99000.57
AAPL130.390.75000.58
GOOG2 516.50-4.1600-0.17
MSFT258.800.44000.17
XOM63.98-0.3500-0.54
WFC44.48-0.9800-2.16
JNJ165.070.58000.35
FB332.90-3.8500-1.14
GE13.42-0.1200-0.89
JPM153.86-1.3200-0.85
Financial StrengthValueIndustryS&P 500US Markets
2.40
3.10
0.14
0.23
68.20
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
86.00
48.50
51.20
37.70
43.64
RevenueValueIndustryS&P 500US Markets
9.20B
87.87
11.87
14.39
Earnings HistoryEstimateReportedSurprise %
Q01 20217.7810.0929.69
Q04 20207.118.7222.64
Q03 20209.527.68-19.33
Q02 20205.596.2912.52
Q01 20204.895.8720.04
Q04 20196.036.589.12
Q03 20195.135.8413.84
Q02 20194.605.2915.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR16.53-4.12Negative
9/2021 QR11.0136.09Positive
12/2021 FY46.8111.72Positive
12/2022 FY38.4842.78Positive
Next Report Date4th Aug 2021
Estimated EPS Next Report16.53
Estimates Count2
EPS Growth Next 5 Years %18.30
Volume Overview
Volume535.63K
Shares Outstanding106.54M
Trades Count14.62K
Dollar Volume584.75M
Avg. Volume918.73K
Avg. Weekly Volume621.13K
Avg. Monthly Volume677.62K
Avg. Quarterly Volume817.12K

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock closed at 527.49 per share at the end of the most recent trading day (a -0.24% change compared to the prior day closing price) with a volume of 547.48K shares and market capitalization of 56.52B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9123 people. Regeneron Pharmaceuticals Inc. CEO is Leonard S. Schleifer.

The one-year performance of Regeneron Pharmaceuticals Inc. stock is -10.4%, while year-to-date (YTD) performance is 9.19%. REGN stock has a five-year performance of 43.92%. Its 52-week range is between 441 and 664.64, which gives REGN stock a 52-week price range ratio of 40.01%

Regeneron Pharmaceuticals Inc. currently has a PE ratio of 14.90, a price-to-book (PB) ratio of 4.68, a price-to-sale (PS) ratio of 6.02, a price to cashflow ratio of 23.10, a PEG ratio of 2.32, a ROA of 23.19%, a ROC of 28.78% and a ROE of 32.18%. The company’s profit margin is 43.64%, its EBITDA margin is 51.20%, and its revenue ttm is $9.20 Billion , which makes it $87.87 revenue per share.

Of the last four earnings reports from Regeneron Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $16.53 for the next earnings report. Regeneron Pharmaceuticals Inc.’s next earnings report date is 04th Aug 2021.

The consensus rating of Wall Street analysts for Regeneron Pharmaceuticals Inc. is Moderate Buy (1.95), with a target price of $622.21, which is +17.13% compared to the current price. The earnings rating for Regeneron Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Regeneron Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Regeneron Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.24, ATR14 : 11.76, CCI20 : 130.01, Chaikin Money Flow : 0.02, MACD : 7.55, Money Flow Index : 63.11, ROC : 6.49, RSI : 62.27, STOCH (14,3) : 85.97, STOCH RSI : 0.66, UO : 60.74, Williams %R : -14.03), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Regeneron Pharmaceuticals Inc. in the last 12-months were: Andrew J Murphy (Option Excercise at a value of $1 018 850), Andrew J Murphy (Sold 20 937 shares of value $12 584 164 ), Arthur Frederick Ryan (Sold 709 shares of value $402 861 ), Bonnie L. Bassler (Option Excercise at a value of $1 002 923), Bonnie L. Bassler (Sold 2 559 shares of value $1 612 210 ), Christine A. Poon (Option Excercise at a value of $1 137 550), Christine A. Poon (Sold 40 000 shares of value $24 048 714 ), Christopher R. Fenimore (Option Excercise at a value of $1 907 015), Christopher R. Fenimore (Sold 7 265 shares of value $4 482 532 ), Daniel P. Van Plew (Option Excercise at a value of $13 434 750), Daniel P. Van Plew (Sold 27 109 shares of value $16 560 737 ), George D. Yancopoulos (Option Excercise at a value of $20 712 050), George L. Sing (Option Excercise at a value of $7 514 542), George L. Sing (Sold 126 050 shares of value $77 406 199 ), Huda Y. Zoghbi (Option Excercise at a value of $1 337 231), Huda Y. Zoghbi (Sold 3 412 shares of value $2 217 800 ), Joseph J. Larosa (Option Excercise at a value of $520 300), Joseph J. Larosa (Sold 4 672 shares of value $2 873 467 ), Joseph L. Goldstein (Option Excercise at a value of $11 756 755), Joseph L. Goldstein (Sold 28 716 shares of value $16 271 124 ), Marion McCourt (Option Excercise at a value of $1 714 650), Marion McCourt (Sold 5 000 shares of value $2 819 430 ), Michael S. Brown (Option Excercise at a value of $5 859 395), Michael S. Brown (Sold 14 596 shares of value $8 393 778 ), N. Anthony Coles (Option Excercise at a value of $3 800), Neil Stahl (Option Excercise at a value of $7 815 575), Neil Stahl (Sold 17 521 shares of value $9 101 459 ), P. Roy Vagelos (Option Excercise at a value of $13 007 500), P. Roy Vagelos (Sold 100 380 shares of value $60 523 056 ), Robert E. Landry (Option Excercise at a value of $16 877 453), Robert E. Landry (Sold 3 656 shares of value $2 338 080 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (52.38 %)
10 (47.62 %)
11 (55.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
10 (47.62 %)
11 (52.38 %)
9 (45.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.95
Moderate Buy
2.05
Moderate Buy
1.90

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.

CEO: Leonard S. Schleifer

Telephone: +1 914 847-7000

Address: 777 Old Saw Mill River Road, Tarrytown 10591-6707, NY, US

Number of employees: 9 123

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

54%46%

Bearish Bullish

56%44%

News

Stocktwits